EGFR and neoplasm: During treatment with anti-EGFR monoclonal antibodies, emergence of RAS and other mutations can be identified in circulating tumour DNA (ctDNA) before clinically apparent disease progression (Diaz et al 2012; Siravegna et al 2015).